365 related articles for article (PubMed ID: 17440076)
1. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
2. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
5. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
6. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis.
Koreny T; Tunyogi-Csapó M; Gál I; Vermes C; Jacobs JJ; Glant TT
Arthritis Rheum; 2006 Oct; 54(10):3221-32. PubMed ID: 17009257
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mediates osteoclastogenesis through two different pathways.
Inoue H; Nishimura K; Oka D; Nakai Y; Shiba M; Tokizane T; Arai Y; Nakayama M; Shimizu K; Takaha N; Nonomura N; Okuyama A
Cancer Lett; 2005 Jun; 223(1):121-8. PubMed ID: 15890244
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of osteoclastogenesis and osteoclast function by apigenin.
Bandyopadhyay S; Lion JM; Mentaverri R; Ricupero DA; Kamel S; Romero JR; Chattopadhyay N
Biochem Pharmacol; 2006 Jul; 72(2):184-97. PubMed ID: 16750176
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.
Barrett JM; Rovedo MA; Tajuddin AM; Jilling T; Macoska JA; MacDonald J; Mangold KA; Kaul KL
Prostate; 2006 May; 66(6):632-50. PubMed ID: 16388503
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
11. Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption.
La VD; Tanabe S; Grenier D
J Periodontal Res; 2009 Apr; 44(2):193-8. PubMed ID: 18705650
[TBL] [Abstract][Full Text] [Related]
12. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
14. Regulation of RANKL-induced osteoclastic differentiation by vascular cells.
Tintut Y; Abedin M; Cho J; Choe A; Lim J; Demer LL
J Mol Cell Cardiol; 2005 Aug; 39(2):389-93. PubMed ID: 15893766
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1alpha,25(OH)D.
Sipos W; Duvigneau JC; Schmoll F; Exel B; Hofbauer G; Baravalle G; Hartl RT; Dobretsberger M; Pietschmann P
J Vet Med A Physiol Pathol Clin Med; 2005 Oct; 52(8):382-7. PubMed ID: 16176565
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
17. Metastatic breast cancer induces an osteoblast inflammatory response.
Kinder M; Chislock E; Bussard KM; Shuman L; Mastro AM
Exp Cell Res; 2008 Jan; 314(1):173-83. PubMed ID: 17976581
[TBL] [Abstract][Full Text] [Related]
18. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]